FISH for HER2/neu - Paraffin Block

The FISH test for HER2/neu is a diagnostic test that uses fluorescent probes to visualize and analyze the HER2/neu gene in tissue samples. This test is used to determine if there is an amplification or overexpression of the HER2/neu gene.

Knowing the HER2/neu status of a breast tumor is critical for treatment planning. Certain drugs specifically target HER2-positive tumors and can be very effective in treating these cancers. The test can also provide prognostic information.

Anyone diagnosed with breast cancer should undergo testing for HER2/neu status as part of the standard diagnostic workup. This information is essential for making informed treatment decisions.

The test is performed on tissue samples that are usually obtained through a biopsy. The tissue is embedded in paraffin blocks, sectioned, and then treated with fluorescent probes that bind specifically to the HER2/neu gene. The tissue is then examined under a microscope.

A positive result indicates that there is amplification or overexpression of the HER2/neu gene. A negative result indicates that the HER2/neu gene is not amplified. This information will help guide treatment decisions.

HER2-positive breast cancers can be treated with drugs that specifically target the HER2 protein, such as trastuzumab (Herceptin) and lapatinib (Tykerb). These may be used in combination with chemotherapy or other treatments.

The FISH test itself does not have side effects, but the biopsy procedure to obtain tissue samples can have risks such as infection, bleeding, or discomfort.

The FISH test for HER2/neu is typically performed on paraffin-embedded tissue samples, which are prepared from biopsy or surgery specimens.

Yes, HER2/neu amplification is often associated with more aggressive forms of breast cancer, so knowing the HER2/neu status can provide prognostic information.

While HER2/neu amplification is most commonly associated with breast cancer, it can also occur in other types of cancer, such as stomach cancer.

The FISH test is considered very reliable for determining HER2/neu status and is often used when other tests, such as IHC, are inconclusive.

If the test is positive, your doctor will discuss treatment options with you, which may include drugs that target HER2.

It’s possible for HER2 status to change, particularly after treatment. Sometimes, tumors that were initially HER2-negative become HER2-positive, and vice versa.

The FISH test for HER2/neu is a crucial diagnostic tool in the management of breast cancer. This test assists in determining the HER2/neu status of the tumor, which has significant implications for treatment planning and prognosis. It is essential to work closely with your doctor to understand the results of this test and to make informed decisions about your care.